VÁŠOVÁ, I., Miroslav PENKA, Roman HÁJEK, Jiří MAYER and E. KRAHULCOVÁ. Fludarabin. Nový purinový analog v léčbě hematologických malignit. (A new purine analog in the treatment of hematologic malignancy. I. Fludarabine). Vnitřní lékařství. Praha: Česk lékařská společnost J. Ev. Purkyně, 1997, vol. 43, No 1, p. 45-50. ISSN 0042-773X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Fludarabin. Nový purinový analog v léčbě hematologických malignit.
Name (in English) A new purine analog in the treatment of hematologic malignancy. I. Fludarabine
Authors VÁŠOVÁ, I. (203 Czech Republic), Miroslav PENKA (203 Czech Republic, guarantor), Roman HÁJEK (203 Czech Republic), Jiří MAYER (203 Czech Republic) and E. KRAHULCOVÁ (203 Czech Republic).
Edition Vnitřní lékařství, Praha, Česk lékařská společnost J. Ev. Purkyně, 1997, 0042-773X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords (in Czech) fludarabin
Keywords in English hematologic malignancy; fludarabine
Tags fludarabine, hematologic malignancy
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 24/6/2009 07:12.
Abstract
V článku autoři popisují účinky nového léku fludarabinu na hematoonkologická onemocnění.
Abstract (in English)
New purine analogues, fludarabine, 2-chlorodeoxyadenosine and 2-deoxycoformycin are remarkably active in generally incurable malignant lymphoproliferative disorders. The first part of the review summarises pharmacological properties, the mechanism of action, toxicity and clinical use of fludarabine. Major clinical experience with fludarabine has been obtained in patients with chronic lymphocytic leukaemia (CLL). In the studies in pretreated patients with CLL, the overall response rate was over 50%. In previously untreated patients with CLL response rate of 75-80% was recorded with a high ratio of complete responses. Fludarabine was found to be active agent in indolent lymphoma in phase I/II. Approximately 60% of patients with follicular lymphoma respond to fludarabine monotherapy. Combination of fludarabine with cytosine arabinoside (ara-C) is now successfully used in the treatment of acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS). Other potential areas of use for fludarabine include hairy-cell leukaemia, Waldenström's macroglobulinaemia and mycosis fungoides. Myelosupression, especially leuko and lymphopenia is the major dose-limiting adverse effect of fludarabine. A long term reduction in CD4+ T cell count may be associated with an increased incidence of opportunistic infections. Other adverse effects such as nausea and vomiting or neurotoxicity are of mild to moderate severity when the recommended dosage is used.
PrintDisplayed: 31/5/2024 10:59